Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
Tuesday, July 21, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Acrivon is set to present its AP3 platform at the AACR D3 Conference, showcasing mechanistic data on ACR-2316, a promising WEE1/PKMYT1 inhibitor. The drug has demonstrated early clinical responses, including partial responses in patients. The presentations aim to emphasize the platform's capabilities in facilitating pathway-based drug discovery and development.
Price reaction · baseline $1.75 (2026-07-21 close) · hit after-hours · clean, no other ACRV news in the window
day 0 close · peak
-4%
Market Sentiment Analysis
POSITIVE FACTORS
Highlighting innovative AP3 platform for drug discovery.
Potential first-in-class drug ACR-2316 showing early clinical responses.
Presentations at a prestigious conference enhance visibility.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+38%
120-day peak, hindsight
Typical move
7.5%
average across 3 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
ACR-2316
Phase 1 · Specific Advanced Solid Tumors
Full Press Release Details
Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic index Early clinical responses, including partial responses (PRs) across multiple AP3-predicted
Frequently Asked Questions
What is Acrivon's AP3 platform?
Acrivon's AP3 platform is designed for streamlined, pathway-based drug discovery and development.
What is ACR-2316?
ACR-2316 is a potential first-in-class WEE1/PKMYT1 inhibitor developed using the AP3 platform.
What were the early clinical responses for ACR-2316?
Early clinical responses for ACR-2316 included partial responses across multiple patients.
Where will Acrivon present its findings?
Acrivon will present its findings at the AACR D3 Conference.